Loading…
Jaguar Health, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in JAGX.
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $488.77 | $883.75 | $7,927.50 | $342,562.50 | |
| P/S | 1.2x | 8.5x | 1.1x | 1.1x | 1.2x |
| P/B | — | — | 1.8x | 2.2x | — |
| EPS | -$803.95 | -$4,574.15 | -$29,542.20 | -$1,129,857.14 | |
| Profit margin | -410.01% | -464.20% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| REVBRevelation Biosciences Inc | $1.05 | 0.0x | 0.4x | — | -154.77% | $4.18M |
| GRIGRI Bio, Inc. | $1.92 | — | 0.4x | — | -142.02% | $4.2M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |
| APVOAptevo Therapeutics Inc. | $2.37 |
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Company description provided by Yahoo Finance.
| -329.30% |
| -423.11% |
| -396.91% |
| ROE | — | — | -528.37% | -832.49% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.0x |
| 0.6x |
| — |
| -420.34% |
| $4.26M |
| TCRTAlaunos Therapeutics, Inc. | $1.61 | — | 3.0x | — | -185.95% | $4.08M |
| ELABPMGC Holdings Inc. | $5.31 | — | 0.2x | — | -105.22% | $4.3M |